Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN

Clinical trials for Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN explained in plain language.

Never miss a new study

Get alerted when new Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN trials appear

Sign up with your email to follow new studies for Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug cocktail targets rare spleen cancer in early trial

Disease control Recruiting now

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of lymphoma that affects the spleen. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. Abo…

Matched conditions: SPLENIC B-CELL LYMPHOMA/LEUKAEMIA WITH PROMINENT NUCLEOLI，SBLPN

Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control

Last updated Jun 27, 2026 08:05 UTC

Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN

Get alerted when new Splenic B-cell lymphoma/leukaemia with prominent nucleoli，SBLPN trials appear

New drug cocktail targets rare spleen cancer in early trial